Besides, 19 patients harboring EGFR mutations, the most common driver mutation of lung cancer, were involved which could shed light on neoadjuvant treatment for EGFR-mutant NSCLC in a way. This evidence concerns the gene EGFR and non-small cell lung carcinoma.